Andriy Luzhetskyyis a principal investigator who has a top track record in genome engineering of actinomycetes. The genetic tools developed in the group of Andriy Luzhetskyy have been distributed to more than 150 laboratories worldwide and became a gold standard in genetic manipulation of actinobacteria. During the last years, the group is focused on the application of synthetic biology approaches to actinomycetes and generated genome-minimized hosts based on Streptomyces albus and S. lividans for heterologous expression of biosynthetic gene clusters. Luzhetskyy’s group creates and tests libraries of synthetic genetic controlling elements for heterologous production of small molecules. Dr. Luzhetskyy published 110 peer-reviewed articles, that results in an h-index of 33. All peer-reviewed articles have been published in one of the top Life sciences journals (Molecular Microbiology, Chemistry and Biology, Metabolic Engineering, Nature Chemical Biology, Angewandte Chemie International etc.). In the past 5 years, Prof. Luzhetskyy has acquired more than 4 million Euro of funding and worked in various national and international projects with academic and industrial partners (e.g. Sanofi, Enzym, BASF, Pfizer, Merk, Gnosis, MyBiotech, PharmBiotec).
Saarland University (USAAR) is a modern mid-sized public university in Southwest Germany near to France, Luxemburg and Belgium with a strong research focus offering a broad range of studies and degrees. Today, 16,900 people are studying in Saarbrücken and Homburg (faculty of medicine), 19 per cent of whom are international students.
Saarland University’s institutional identity is defined by three main areas of research and teaching: “Computer Sciences”, “NanoBioMed Sciences”, and “European Studies and Internationality”. The campus of USAAR is also home for other major research institutions, such as Max Planck, Helmholtz, Leibniz and Fraunhofer institutes or the German Research Center for Artificial Intelligence. USAAR is very active in national and international research collaborations in different funding instruments and settings. Its Department for Research Management and Transfer fully supports USAAR's scientists in acquiring and administering their research projects and in translating their research results into business.
The Department of Pharmaceutical Biotechnology led by Prof. Andriy Luzhetskyy is focused on biosynthetic engineering of bioactive molecules producers. The interdisciplinary and international team comprises 20 members with expert knowledge in metabolic engineering, synthetic biology, molecular biology and genetics, bioinformatics, microbiology and analytical chemistry. A team of six permanently employed coworkers operates the highly complicated infrastructure and keeps expertise.
Andriy Luzhetskyy and his group will be responsible for providing expertise on cloning and refactoring of biosynthetic gene clusters responsible for antibiotic production. The group possesses a comprehensive library of synthetic genetic controlling elements, biosynthetic gene clusters, improved chassis for heterologous expression and production of new antibiotics. Andriy Luzhetskyy will coordinate actions on standardization of genetic tools, controlling elements and chassis to be used in synthetic biology-based development of antibiotic. Furthermore, his group has access to unique actinobacteria strain and extract collections comprising more than 2000 strains and bioactive culture extracts.